NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 43.9% and is now trading at $6.85.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) released its earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $21.50 million for the quarter, compared to the consensus estimate of $21.50 million. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%.
View Cerus' earnings history.

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

4 Wall Street analysts have issued twelve-month price targets for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Cerus.

Media stories about CERS stock have trended extremely negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Neogen (NEOG), Haemonetics (HAE), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Opko Health (OPK), Immunomedics (IMMU), Advanced Micro Devices (AMD), Pfizer (PFE) and ACADIA Pharmaceuticals (ACAD).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%), Bank of New York Mellon Corp (0.43%) and Goldman Sachs Group Inc. (0.36%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Premier Asset Management LLC, Raymond James & Associates, Macquarie Group Ltd., Personal CFO Solutions LLC, and Leap Investments LP. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, EAM Investors LLC, Sumitomo Mitsui Trust Holdings Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Swiss National Bank, Raymond James Financial Services Advisors Inc., and California Public Employees Retirement System. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $6.85.

Cerus has a market capitalization of $1.14 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]